

Investing in healthcare – the entrepreneur's view

Daniela Pavlić

Country Director Baltics - AstraZeneca




EE-1919-11-23-OTHER

A robust economy is built on scientific innovation.

How keeping health a priority might be a prescription for prosperity

Changing attitudes towards healthcare is needed to make it priority, reflected in investments

% of GDP, 2020








The more we invest in healthcare, the more quality of life and healthy life years improve

Our World in Dat<u>a</u>

2019

Disease burden vs. health expenditure per capita, 2019 Total disease burden from all causes, measured as the number of Disability-Adjusted Life Years (DALYs) per 100,000 individuals, versus health expenditure per capita measured in current international-\$



- Health expenditure per capita → correlation with people lives
- Countries with similar GDP invest in Healthcare more per capita
- ⇒ Higher investments result in lower disease burden

2000

OurWorldInData.org/burden-of-disease • CC BY

Investing in healthcare: benefits outweigh the cost



- \Rightarrow Lower disease burden translates into higher labor force participation & productivity
- ⇒ Investment in prevention brings return long-term, whilst investing in screening and treatment benefits already today

Upper-middle-Range of estimated GDP growth potential by country by 2040, % income countries 10 11 12 Not included 0 Czech Republic Austria Belgium Latvia Lithuania Croatia Portugal Bulgaria Slovenia Denmark Estonia Finland Germany 2.8 France Hungary Greece Italy $2 \times$ Ireland Netherlands Romania Poland 1.4 Slovakia Spain Sweden Switzerland \Rightarrow For each 1\$ invested, United Kingdom an economic return of 2\$ is possible

The GDP growth opportunity from health improvement varies across the region.

Note: The boundaries and names shown on this map do not imply official endorsement or acceptance by McKinsey & Company. Source: McKinsey Global Institute analysis

McKinsey & Company

Health improvement results in 10% GDP growth opportunity


https://ourworldindata.org/burden-of-disease

https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/prioritizing-health-a-prescription-for-prosperity https://ourworldindata.org/burden-of-disease#income-and-disease-burden-from-communicable-diseases



Despite significant improvement over past decades, AstraZeneca AstraZeneca AstraZeneca Estonian working age population still loses 1/3 of their life to diseases

DALY rates from non-communicable diseases (NCDs), 1990 to 2019 Age-standardized DALY (Disability-Adjusted Life Year) rates per 100,000 individuals from non-communicable diseases (NCDs). DALYs are used to measure total burden of disease - both from years of life lost and years lived with a disability. One DALY equals one lost year of healthy life.



ld	
----	--

15–69	EE	SE	FI	DK	NO	LT	LV
population	CC	JE	гі	DK	NU	L1	LV
DALY in years	0,267	1,4	0,76	0,935	0,774	0,658	0,451
DALY %	32%	22%	22%	25%	22%	37%	38%

 \Rightarrow Up to 10% more than Nordic countries


⇒ 32% DALY loss translates into more than 1 billion EUR in yearly tax income

https://ourworldindata.org/burden-of-disease https://andmed.stat.ee/et/stat/majandus_rahandus_valitsemissektori-rahandus_maksud/RR027 Working population 920 000 ppl; Avg tax income per person in 2021 – 6964 EUR



Baltics lag behind in accessing effective and innovative treatments

WAIT report: measures access to innovative medicines in Europe



innovative medicines

European

countries




WAIT – Waiting to Access Innovative Therapies
IQVIA in partnership with EFPIA
Latest update published in April '23

"IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes."



Estonian patients would benefit from wider access to innovation



> Only less than a fifth of innovative medicines are available in Estonia as of 1st Jan '23

S

AstraZeneca

Where do we lose most of our lives...

https://ourworldindata.org/burden-of-disease

Cardiovascular diseases

Musculoskeletal disorders Neurological disorders

> Unintentional injuries Mental disorders

> > **Digestive diseases**

Substance use disorders

Diabetes and kidney diseases

Cancers

Other NCDs

Nearly half of all lives lost derive from cardiovascular & oncological diseases

17.66%

Share of total disease burden by cause, Estonia, 2019

Total disease burden, measured in Disability-Adjusted Life Years (DALYs) by sub-category of disease or injury. DALYs measure the total burden of disease – both from years of life lost due to premature death and years lived with a disability. One DALY equals one lost year of healthy life.

6.3%

5.86% 5.71%

5.27%

4.98%

4.69%

4.12%

3.78%

Biggest impact

to disease burden reduction could be achieved via investing in prevention and treatment of cardiovascular and oncological diseases

Sense organ diseases 3.21% Self-harm 1.73% Transport injuries 1.71% **Respiratory diseases** 1.69% **Respiratory infections and TB** 1.53% Skin diseases 1.45% Interpersonal violence 0.7% Neonatal disorders 0.61% Enteric infections 0.51% HIV/AIDS and STIs 0.48% Nutritional deficiencies 0.4% Malaria & neglected tropical diseases 0.13% Maternal disorders 0.02% **Conflict & terrorism** <0.01% Natural disasters | <0.01% 0% 5% 10% 15% 20% 25% Source: IHME, Global Burden of Disease (2019) OurWorldInData.org/burden-of-disease • CC BY

Note: Non-communicable diseases are shown in blue; communicable, maternal, neonatal and nutritional diseases in red; injuries in grey.



27.29%





The growing chronic disease burden across Europe



21% of Europeans aged >65 years



50 million living with >1 chronic disease



>4 million deaths annually



Cancer is becoming the major health concern globally and AstraZeneca AstraZeneca



Professor Toivo Maimets: "In several countries, cancer deaths already outweigh the cardiovascular disease related deaths"

In Estonian Cancer Society 30th anniversary Conference - 16th Sept 2022


Lung cancer - leading cause of cancer death globally, accounts for 15% among all cancers costs



The centre Policy Partnership
and endorsed by the International Association for the Study of Lung Cancer, It was initiated
and funded by AstraZenee, a founding partner of the Lung Ambitton Alliance.

⇒Estonia leading the way in lung cancer screening

Only ~17% of oncology medicines available in Estonia



> Estonia is behind several countries who are on the same level or below from economic perspective


AstraZeneca

A call-out for positive change, achieved via partnership and collaboration



Health as national wealth: couple of aspects might contribute and address sustainability and resiliance of HealthCare systems

services more frequently



Predicatbality



Partnership for Health System Sustainability and Resilience (PHSSR)

PHSSR is a global collaboration working with governments and healthcare systems to shape the future of and build health system resilience to withstand future crises and to sustainability improve population health in the long term

Robust research focused on high-impact areas, delivered at pace


Action-orientated, evidence-informed policy recommendations

Research framework developed by the LSE looking at:

- 1. Governance
- 2. Financing
- 3. Workforce
- 4. Medicines and Technology

- 5. Service delivery
- 6. Population health
- 7. Environmental sustainability

Reach of PHSSR in EU & Canada



Implementation across 13 countries (Phase 1 & 2)

In collaboration with academia and public and private sectors







WH® Foundation





19

Partnership for Health System Sustainability and Resilience (PHSSR)

Robust research focused on high-impact areas


Action-orientated, evidence-informed policy recommendations

Based on collaboration across academia and the public and private sectors to effect positive change together

To date, PHSSR has assessed 30 countries and is active across 13 EU Member States



It Starts with HEALTH



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com